Abbott Laboratories Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.3%projected annual EPS growth
Analyst Coverage
25analysts covering
FY Revenue (est.)
$50.3Bnext fiscal year
FY EPS (est.)
$5.52next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 21 Oct 2026 |
| Q4 2026 Earnings Release | 21 Jan 2027 |
Monitoring Framework
Key Performance Indicators
Comparable Sales Growth Quarterly4.8%Target: 6.5% to 7.5% for FY 2026
Adjusted Diluted Earnings Per Share (EPS) Quarterly1.3Target: $5.45 to $5.60 for FY 2026
Medical Devices Comparable Sales Growth Quarterly8.4%Target: High-single to low-double digit growth
Watch Items
- Exact Sciences Integration and Cancer Diagnostics GrowthTrigger: Slowing of Cologuard sales growth below mid-teensAction: Re-evaluate synergy assumptions and goodwill impairment risks on the $23 billion acquisition.
- China Volume-Based Procurement (VBP) ImpactTrigger: Accelerated decline in China diagnostics and device salesAction: Adjust emerging market growth forecasts and shift commercial focus to Latin America and Southeast Asia.
- U.S. Mitral Valve Competitive IntensityTrigger: Market share loss in Structural Heart to Edwards LifesciencesAction: Accelerate clinical trials and commercial rollout of next-generation structural heart devices.
Research as of 2 Sep 2026